Nexalis Therapeutics Limited · ASX:NX1
Nexalis Therapeutics — Shareholder Meeting (May 2026)
15 slides from Nexalis Therapeutics's shareholder meeting presentation, May 29, 2026
Slide 1: 2026 Annual General Meeting
2026 Annual General Meeting 29 May 2026
Slide 2: Welcome and Agenda
WELCOME AND AGENDA Online attendees • If you have an IT-related issue, please click on the “Raise Hand” button • If there is a question relating to the resolution, shareholders can ask questions by clicking on the Q&A button and typing in your question Agenda • Resolution 1 • Poll on Resolution 1 •
Slide 3: 2025 Financial Statements
2025 FINANCIAL STATEMENTS To consider and receive the financial statements of the Company for the year ended 31 December 2025, consisting of the Financial Report and the Reports of the Directors and Auditor. As required by Section 317 of the Corporations Act, the financial statements of the Company
Slide 4: Resolution 1
RESOLUTION 1 To consider and, if thought fit, to pass with or without amendment, the following Resolution as a non- binding ordinary resolution: “That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Repor
Slide 5: Poll on Resolution 1
Poll on Resolution 1 Poll opened by the Chair Click on “For”, “Against” or “Abstain” Shareholders and visitors who are not voting, click “Skip Poll” Poll closed by the Chair Results will be tallied whilst the Chair convenes a short break 5
Slide 6: Resolution 2
RESOLUTION 2 If less than 25% of the votes cast on Resolution 1 are voted against adoption of the Remuneration Report, the Chair will withdraw Resolution 2. To consider and, if thought fit, to pass with or without an amendment, the following Resolution as an ordinary resolution: “That, for the purpo
Slide 7: Resolution 3
RESOLUTION 3 This resolution has been withdrawn
Slide 8: Resolution 4
RESOLUTION 4 To consider and, if thought fit, to pass with or without an amendment, the following Resolution as a special resolution: “That for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue up to that number of Equity Securities equal to
Slide 9: Resolution 5
RESOLUTION 5 To consider and, if thought fit, to pass with or without an amendment, the following Resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to the equivalent of $85,848 of Share Rights
Slide 10: Resolution 6
RESOLUTION 6 This resolution has been withdrawn
Slide 11: Resolution 7
RESOLUTION 7 To consider and, if thought fit, to pass with or without an amendment, the following Resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to the equivalent of $50,400.00 of Share Rig
Slide 12: Resolution 8
RESOLUTION 8 To consider and, if thought fit, to pass with or without an amendment, the following Resolution as an ordinary resolution: “That, for the purposes of Listing Rule 7.4 and for all other purposes, shareholders ratify the issue 6,900,000 Placement Shares and 3,450,000 Placement Options sub
Slide 13: Resolution 9
RESOLUTION 9 To consider and, if thought fit, to pass with or without an amendment, the following Resolution as an ordinary resolution: “That, for the purposes of Listing Rule 7.4 and for all other purposes, shareholders ratify the issue of 780,000 Shares at $0.025 per Share on the terms and conditi
Slide 14: Poll on Resolutions 2 to 9
Poll on Resolutions 2 to 9 Poll opened by the Chair Click on “For”, “Against” or “Abstain” on each resolution Shareholders and visitors who are not voting, click “Skip Poll” Poll closed by the Chair Results will be released on the ASX following the meeting Meeting formally closed 14
Slide 15: General Q&A
General Q&A Thank you for your attendance at today’s meeting T: +61 3 9070 1221 E: investors@nexalistherapeutics.com W: https://www.nexalistherapeutics.com
Nexalis Therapeutics — Shareholder Meeting (May 2026) on 6ix